14 results
6-K
EX-99.2
VALN
Valneva SE
26 Mar 24
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
6:44am
the understanding that the primary recipients of a Zika vaccine are anticipated to be women of childbearing age, potentially including those who are pregnant
6-K
EX-99.1
VALN
Valneva SE
13 Oct 23
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
5:00pm
, Spain, Valneva will display a poster titled “Safety of Live Attenuated Vaccines in Immunocompromised Patients and Pregnant Women: A Systematic Review
6-K
EX-99.2
VALN
Valneva SE
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
whole virus vaccine adjuvanted with alum for a target population of women of reproductive age, which may include pregnant women, and a secondary target
6-K
EX-1
2az1px3d7slaaunt9s6
4 May 23
Current report (foreign)
11:38am
424B5
wmd5vq9yhc3wgeo5e62p
30 Sep 22
Prospectus supplement for primary offering
4:09pm
424B5
x462odoc tqeloujb
28 Sep 22
Prospectus supplement for primary offering
8:24pm
6-K
EX-99.2
c1og9p9un5ktljo0wk
8 Sep 22
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
3:39pm
F-3
xk7glii337xed
12 Aug 22
Shelf registration (foreign)
4:42pm
20-F
EX-4.3
tcr51sfkbiu xok2zw4
24 Mar 22
Annual report (foreign)
12:32pm
F-1
EX-10.8
snwdufopk0
9 Apr 21
Registration statement (foreign)
4:06pm
DRS/A
EX-10.8
2zl2j
24 Feb 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next